Journey Medical Reports Q3 2026 Revenue Growth Driven by Emrosi Demand
Journey Medical (DERM) reported third-quarter revenue of $19 million, an 8% increase year-over-year, fueled largely by the strong commercial performance of its rosacea treatment, Emrosi. Emrosi revenue surged 84% to $9 million as prescription volumes and payer reimbursements improved. The company achieved positive Adjusted EBITDA of $3.5 million for the second consecutive quarter, up from $1.4 million in the prior-year period. Operational highlights include reaching its annual goal for unique prescribers early, with over 5,000 writers currently prescribing Emrosi. While the company reported a GAAP net loss of $1.3 million, this represents a narrowing loss compared to the previous year. Looking ahead, management expects further growth following the addition of a national health plan covering over 25 million lives to the Emrosi formulary in January 2027.
Topics: Adjusted EBITDA Emrosi Sales GAAP Net Loss Gross Margin Revenue Growth